Literature DB >> 9765454

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

J F Richmond1, S Lu, J C Santoro, J Weng, S L Hu, D C Montefiori, H L Robinson.   

Abstract

DNA vaccination is an effective means of eliciting strong antibody responses to a number of viral antigens. However, DNA immunization alone has not generated persistent, high-titer antibody and neutralizing antibody responses to human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env). We have previously reported that DNA-primed anti-Env antibody responses can be augmented by boosting with Env-expressing recombinant vaccinia viruses. We report here that recombinant Env protein provides a more effective boost of DNA-initiated antibody responses. In rabbits primed with Env-expressing plasmids, protein boosting increased titer, persistence, neutralizing activity, and avidity of anti-Env responses. While titers increased rapidly after boosting, avidity and neutralizing activity matured more slowly over a 6-month period following protein boosting. DNA priming and protein immunization with HIV-1 HXB-2 Env elicited neutralizing antibody for T cell line-adapted, but not primary isolate, viruses. The most effective neutralizing antibody responses were observed after priming with plasmids which expressed noninfectious virus-like particles. In contrast to immunizations with HIV-1 Env, DNA immunizations with the influenza virus hemagglutinin glycoprotein did not require a protein boost to achieve high-titer antibody with good avidity and persistence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765454      PMCID: PMC110326     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Enzyme-linked immunosorbent assay determination of specific rubella antibody levels in micrograms of immunoglobulin G per milliliter of serum in clinical samples.

Authors:  P O Leinikki; I Shekarchi; P Dorsett; J L Sever
Journal:  J Clin Microbiol       Date:  1978-10       Impact factor: 5.948

2.  Affinity distributions of antigen-specific IgG in patients with multiple sclerosis and in patients with viral encephalitis.

Authors:  R W Luxton; E J Thompson
Journal:  J Immunol Methods       Date:  1990-08-07       Impact factor: 2.303

3.  Measuring vaccine-induced HIV neutralization: report of a workshop.

Authors:  C V Hanson
Journal:  AIDS Res Hum Retroviruses       Date:  1994-06       Impact factor: 2.205

Review 4.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

Authors:  C K Leonard; M W Spellman; L Riddle; R J Harris; J N Thomas; T J Gregory
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

7.  DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates.

Authors:  B Wang; J Boyer; V Srikantan; L Coney; R Carrano; C Phan; M Merva; K Dang; M Agadjanan; L Gilbert
Journal:  DNA Cell Biol       Date:  1993-11       Impact factor: 3.311

8.  V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

Authors:  D C Montefiori; B S Graham; J Zhou; J Zhou; R A Bucco; D H Schwartz; L A Cavacini; M R Posner
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.

Authors:  B S Graham; G J Gorse; D H Schwartz; M C Keefer; M J McElrath; T J Matthews; P F Wright; R B Belshe; M L Clements; R Dolin
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

10.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

View more
  43 in total

1.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

4.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

Review 5.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

Review 6.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

7.  What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

Authors:  Marina R Alexander; Rajesh Ringe; Rogier W Sanders; James E Voss; John P Moore; Per Johan Klasse
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

8.  Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.

Authors:  M K Song; S W Lee; Y S Suh; K J Lee; Y C Sung
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 10.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.